Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Brainstorm Cell Therapeutics Inc is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of USD$160 million.
|Latest market close||USD$4.81|
|52-week range||USD$3.81 - USD$17.95|
|50-day moving average||USD$6.4321|
|200-day moving average||USD$11.4115|
|Wall St. target price||USD$29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.88|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||3.89%|
|1 month (2020-12-18)||-9.59%|
|3 months (2020-10-19)||-61.12%|
|6 months (2020-07-17)||-67.01%|
|1 year (2020-01-17)||10.57%|
|2 years (2019-01-18)||38.62%|
|3 years (2018-01-18)||39.02%|
|5 years (2016-01-15)||131.25%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-85.98%|
|Return on equity TTM||-288.4%|
|Market capitalisation||USD$160 million|
TTM: trailing 12 months
There are currently 6.4 million Brainstorm Cell Therapeutics shares held short by investors – that's known as Brainstorm Cell Therapeutics's "short interest". This figure is 5.9% down from 6.8 million last month.
There are a few different ways that this level of interest in shorting Brainstorm Cell Therapeutics shares can be evaluated.
Brainstorm Cell Therapeutics's "short interest ratio" (SIR) is the quantity of Brainstorm Cell Therapeutics shares currently shorted divided by the average quantity of Brainstorm Cell Therapeutics shares traded daily (recently around 2.3 million). Brainstorm Cell Therapeutics's SIR currently stands at 2.72. In other words for every 100,000 Brainstorm Cell Therapeutics shares traded daily on the market, roughly 2720 shares are currently held short.
However Brainstorm Cell Therapeutics's short interest can also be evaluated against the total number of Brainstorm Cell Therapeutics shares, or, against the total number of tradable Brainstorm Cell Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brainstorm Cell Therapeutics's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Brainstorm Cell Therapeutics shares in existence, roughly 200 shares are currently held short) or 0.2386% of the tradable shares (for every 100,000 tradable Brainstorm Cell Therapeutics shares, roughly 239 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brainstorm Cell Therapeutics.
Find out more about how you can short Brainstorm Cell Therapeutics stock.
We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.
Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 16 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.
Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $3.81 up to $17.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is 0.4084. This would suggest that Brainstorm Cell Therapeutics's shares are less volatile than average (for this exchange).
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.